Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
124.30
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Novo Nordisk A/S ADR
< Previous
1
2
3
4
Next >
Can Diabetes, Weight-Loss Drugs Get Even Better?
October 30, 2023
EQNX::TICKER_START (NASDAQ:LEXX,NYSE:NVO:NYSE:PFE,NYSE:MRK,NASDAQ:AZN) EQNX::TICKER_END
Via
FinancialNewsMedia
Global Diabetes Care Market Size Expected To Reach $41.71 Billion By 2027
October 25, 2023
EQNX::TICKER_START (OTCPK:CNER),(NYSE:NVO),(NASDAQ:TNDM),(NASDAQ:DXCM),(NASDAQ:LXRX) EQNX::TICKER_END
Via
FinancialNewsMedia
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders
October 19, 2023
EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
Is the Ozempic-Driven DexCom Selloff Overdone?
October 18, 2023
Has glucose monitor maker DexCom corrected too much on fears of lost sales due to weight loss and diabetes drugs made by Novo Nordisk and Eli Lilly?
Via
MarketBeat
Snack Maker Mondelez Int'l Is Down but Not Out
October 16, 2023
If Mondelez beats consensus for Q3 and can offer reassurance about the potential impact of Ozempic, investors’ appetite for chewed up snack makers may improve.
Via
MarketBeat
Will Higher Ozempic Use Mean Slimmed-Down Food Sales?
October 12, 2023
Novo Nordisk's Ozempic, a weight loss drug, is making waves in the food industry, raising concerns about its effect on sales of calorie-laden products.
Via
MarketBeat
Obesity Drug Boom, Split Make This Stock a Heavy Bargain
October 09, 2023
Ozempic users may be losing their appetites for sweets…but Novo Nordisk is one Danish treat that the market may only get hungrier for.
Via
MarketBeat
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
October 02, 2023
Via
AB Newswire
Topics
Death
Exposures
Death
Product Safety
Flee to Healthcare Stocks if Recession Rears its Head?
September 20, 2023
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Could Ely Lilly Be the Best Pharma Stock to Own Now and Forever?
September 19, 2023
Eli Lilly & Co. stock has been on a tear, trading up 57.7% year-to-date on the strength of its industry-leading medications and highly-anticipated pipeline
Via
MarketBeat
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
September 01, 2023
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
MarketBeat Week in Review – 8/7 - 8/11
August 12, 2023
The latest inflation readings failed to provide clarity for investors as stocks had a turbulent week and the MarketBeat team was covering the top stories
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Economy
Interest Rates
Novo Nordisk Soars To New High On Weight-Loss Drug Trial Results
August 09, 2023
Novo Nordisk's stock surged 16% on preliminary results of clinical trials showing its weight-loss drug Wegovy reduces risk of cardiovascular disease by 20%.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush
July 24, 2023
A bid to acquire Versanis boosts Eli Lilly & Co. by 2.80% in the past week, as the competition to develop the most effective weight-loss drug intensifies.
Via
MarketBeat
InvestorNewsBreaks – Novo Nordisk (NYSE: NVO) Featured in Analysis Report
May 26, 2023
Via
Investor Brand Network
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
May 18, 2023
Big pharma stocks Novartis, Eli Lilly, Merck, and Novo Nordisk are outperforming the market, driven by successful drugs and strong earnings growth.
Via
MarketBeat
Topics
Economy
Exposures
Economy
The Turnaround for Weight Watchers is Taking Shape
May 16, 2023
Weight management meals and services provider WW International Inc. (NYSE: WW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares
Via
MarketBeat
Can Teladoc Stock Be Resuscitated?
May 01, 2023
Virtual healthcare services company Teladoc Health Inc. (NYSE: TDOC) has had a treacherous journey rising to a high of $308 in Feb 2021 and falling to a post-
Via
MarketBeat
Exposures
COVID-19
Here are 2 Top Drug Makers Leading the Way in Weight Loss Drugs
April 17, 2023
The topic of weight loss drugs has been making recent headlines. The positive phase 1 clinical trial for Viking Therapeutics Inc. (NASDAQ: VKTX) GLP-1 treatme
Via
MarketBeat
Novo Nordisk Charges Higher and Could be Just Getting Started
April 13, 2023
Novo Nordisk stock continues to move higher after announcing a partnership with Aspect Biosystems; but at 47x earnings this is still an expensive stock
Via
MarketBeat
Weight Watchers Reshapes Itself with a Game-Changer Acquisition
April 11, 2023
Weight management meals and services provider WW International Inc. (NYSE: WW) spike over 25% as it closed its acquisition of telehealth weight loss platform
Via
MarketBeat
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
March 09, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
February 10, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
EXL Announces Appointment of Andreas Fibig to Board of Directors
January 12, 2023
From
ExlService Holdings, Inc.
Via
GlobeNewswire
Global Drug Delivery Systems Market Size Projected to Reach $71.75 Billion By 2029
January 12, 2023
EQNX::TICKER_START (NASDAQ:STSS),(NYSE:BDX),(NYSE:CAH),(NYSE:NVO),(OTCPK:TRUMY),(NASDAQ:STSSW) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
December 19, 2022
Eli Lilly & Co may be struggling with supply-side issues but new partnerships and a healthy dividend are helping to keep up their momentum
Via
MarketBeat
Amgen Shares Leap Higher On Upbeat Outlook For Obesity Treatment
October 13, 2022
Shares of Amgen soared 5.72% Tuesday and added to those gains Wednesday. The gap-up followed a Morgan Stanley upgrade and increase to the price target.
Via
MarketBeat
Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst
September 01, 2022
In 2016, Americans spent roughly $380 billion on lower back and neck pain. In the same year, medical costs for adult obesity in the United States were $260.6 billion. That’s why BioRestorative...
Via
TheNewswire.com
Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated
August 18, 2022
Americans with diabetes have been relying on insulin injections to manage their illness for decades. Those injections can be painful, expensive and inconvenient. The daily invasive testing regimen adds...
Via
TheNewswire.com
Exposures
Product Safety
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
July 26, 2022
Palm Beach, FL – July 26, 2022 – FinancialNewsMedia.com News Commentary – As COVID-19 vaccines for kids achieve the Centers for Disease Control and Prevention (CDC) recommendation, concern it could...
Via
FinancialNewsMedia
Exposures
COVID-19
Product Safety
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.